Painkiller Developer Collegium Pharmaceutical Eyes $86M IPO
Venture capital-backed Collegium Pharmaceutical Inc., a biotech developing a portfolio of abuse-deterrent drugs to treat chronic pain, on Thursday filed for an initial public offering that would raise $86.3 million, largely to...To view the full article, register now.
Already a subscriber? Click here to view full article